Advertise on podcast: Gastroenterology & Endoscopy

Welcome to this week's Gastroenterology and Endoscopy News Roundup, where we bring you the most important updates and research findings for gastroenterology professionals. This episode covers five critical stories from the week of October 21-28, 2025, including new clinical guidelines, groundbreaking research on procedure safety, and the latest technological innovations in endoscopy. 1. AGA Releases Updated Barrett's Esophagus Surveillance Guideline The American Gastroenterological Association has published a significant update to its clinical practice guideline on Barrett's esophagus surveillance. The new guideline represents a paradigm shift from uniform monitoring to a risk-based, individualized approach. Clinical Impact: This guideline helps optimize resource allocation while improving early detection of neoplasia in higher-risk patients. 2. OCULUS Trial: Holding GLP-1 Agonists Before Endoscopy Reduces Risk The OCULUS randomized controlled trial, presented at ACG 2025, provides the first RCT evidence on managing GLP-1/GIP-1 receptor agonists before upper endoscopy. Clinical Impact: Strong evidence for holding these increasingly common medications before elective upper endoscopy to ensure patient safety and reduce aspiration risk. 3. Landmark Study Reveals 22% of Esophageal Cancers Missed on Endoscopy A large population-based study from Finland and Sweden analyzed over 15,000 Barrett's esophagus patients and uncovered concerning rates of post-endoscopy esophagogastric cancers (PEEC). Clinical Impact: Highlights urgent need for quality metrics in upper endoscopy, similar to adenoma detection rates in colonoscopy, to reduce missed cancers. 4. Fujifilm Launches ELUXEO 8000 Endoscopic Imaging System FUJIFILM Healthcare Americas has unveiled its next-generation endoscopy platform with enhanced imaging capabilities. Clinical Impact: Backward compatibility offers practical upgrade path for existing users while enhancing diagnostic and therapeutic capabilities. 5. FDA Approves Once-Monthly Omvoh Injection for Ulcerative Colitis The FDA has approved a more convenient maintenance regimen for Eli Lilly's mirikizumab-mrkz (Omvoh) for moderately to severely active ulcerative colitis. Clinical Impact: Simplified treatment regimen may improve patient adherence and reduce injection burden. Sponsor This episode is sponsored by DigestiveJobs.com DigestiveJobs.com is the leading career resource for gastroenterology and endoscopy professionals. Whether you're seeking new opportunities, looking to hire talented clinicians, or exploring career advancement, DigestiveJobs.com connects you with the best positions and candidates in the field. Visit DigestiveJobs.com to explore current opportunities and advance your career in gastroenterology. https://www.gastroendopod.com

In this episode, we cover five crucial updates shaping gastroenterology and endoscopy practice in 2025. From the practice-changing ENDURO trial comparing endoscopic to surgical approaches for malignant gastric outlet obstruction, to the latest EASL hepatitis B management guidelines, AI applications in endoscopy, sedation innovations, and biomarker-driven approaches to IBS. Resources & Links ENDURO Trial & EUS-Guided Gastroenterostomy ENDURO Study Protocol - Trials JournalENDURO Trial Results - The Lancet Gastroenterology & HepatologyEUS-GE Overview - Gastroenterology & Endoscopy NewsProspective Study - Gastrointestinal EndoscopyEASL 2025 Hepatitis B Guidelines EASL HBV Guidelines 2025 - Journal of HepatologyEASL Guidelines Summary - EASL WebsiteHBV Guidelines PDF - Hepatitis B FoundationAI in Endoscopy AI and Polyp Detection Review - PMCAI-Assisted Colonoscopy Meta-Analysis - Annals of Internal MedicineUse of AI in Colonoscopy - Gastrointestinal EndoscopyEndoscopist Deskilling Study - The LancetBibliometric Analysis - Frontiers in MedicineSedation Innovations Remimazolam Review - Clinical EndoscopyRemimazolam vs Propofol Meta-Analysis - British Journal of AnaesthesiaRemimazolam Comprehensive Review - World Journal of GI EndoscopyRemimazolam Real-World Study - BMC GastroenterologySafety and Efficacy Comparison - BMC AnesthesiologyIBS Biomarkers & Microbiome 2025 Seoul Consensus on IBS - PMC16S rRNA Microbiome Biomarkers for IBS - PMCInternational Consensus on Microbiome Testing - Gut Microbiota for HealthGut Microbiome Resilience Review - Frontiers in MicrobiologyThis podcast is for educational purposes only and does not constitute medical advice. Always consult current guidelines and use clinical judgment when making treatment decisions. https://www.gastroendopod.com

In this quick-hit episode, we cover the freshest guidelines reshaping IBD, colorectal surveillance, gastric premalignancy, and gastroparesis management. Dive into cutting-edge research on AI for efficiency, targeted therapies, H. pylori strategies, advanced endoscopy, and cost-saving insights. Plus, spotlight on new tech warnings, bariatric devices, GERD diagnostics, and the game-changing FDA approval for subcutaneous Tremfya in UC. Perfect for busy GI pros—actionable takeaways to level up your practice. Key Segments and Highlights: Guidelines Rundown:BSG on IBD: Enhanced primary care pathways, CRC risk stratification, and patient adherence strategies to reduce post-colonoscopy cancers.ACG on Gastric Premalignancy: First-ever guidance on atrophic gastritis, GIM, dysplasia—focus on H. pylori eradication and tailored surveillance.BSG on Colorectal Surveillance: Clear start/stop criteria post-polypectomy and in IBD, with tips for better patient buy-in.AGA on Gastroparesis: 12 recs for diagnosis (scintigraphy) and treatments (prokinetics, G-POEM)—emphasizing personalized, multidisciplinary care.Rome/International on Gastroparesis: Aligns with AGA, adds psychosocial screening and global non-pharma standards. Takeaway: Download from AGA/ACG/BSG sites and audit your protocols.Research Pulse:AI in Guideline Development (AGA Pilot): Cuts review time/costs dramatically for Crohn's biologics—use with human validation.Targeted Drug Delivery: Nanoparticles for IBD/motility; watch for retention improvements.H. pylori in MI Patients (ESC Data): Selective screening for high-risk antiplatelet users to curb GI bleeds.EUS-Guided Gastroenterostomy: Standardization boosts success >90%; includes troubleshooting videos.ASIDE Gastroenterology New Issue: Covers MMF in IBD, tofacitinib in peds UC, ESD aids, gastric cancer immunotherapy, and more.Optical Enhancement Endoscopy RCT: 92% sensitivity for gastric metaplasia/neoplasia—upgrade for high-risk screens.Hospital Affiliation Costs Study: Independents save 20-30% without quality loss; implications for value-based care. Takeaway: Subscribe to journals and experiment with AI cautiously.Devices, Tech, and Approvals:Medical AI Warnings: Address biases in GI datasets; great for polyps, risky for diverse monitoring.ESGE on Bariatric Endoscopy: Devices like balloons and duodenal resurfacing—10-15% weight loss, low AEs; await long-term RCTs.New GERD Tools: AFS (EGJ integrity), Milan (manometry), pHoenix (AET), COuGH RefluX (symptoms), Lyon (integrated phenotyping)—revolutionize grading.FDA Approval: SubQ Tremfya for UC: 50% endoscopic response at Week 12; convenient induction sans IV. Takeaway: Train on AI pitfalls and adopt one GERD tool quarterly.Themes & Standouts: Personalization dominates, AI as a tool (not takeover), tech for precision. Revamp gastroparesis care, smart H. pylori screens, and embrace subQ Tremfya. Resources: Links to guidelines, studies, and journals in the episode description. Submit Q&A via app/email. Next up: UEG Week previews! Sponsored by digestivejobs.com https://www.gastroendopod.com

This week's episode is packed with breakthrough developments that could reshape gastroenterology practice. We dive deep into the potentially transformative TL1A inhibitors showing remarkable results in IBD, explore the first-ever global consensus guidelines for managing IBD during pregnancy, and discuss how a simple blood test is revolutionizing colorectal cancer screening. Plus, we'll look at cutting-edge capsule technology that could disrupt traditional endoscopy and new research revealing the powerful connection between social factors and gut health. #IBD #CrohnsDisease #UlcerativeColitis #Pregnancy #ColorectalCancer #Screening #Endoscopy #Innovation #Research #Guidelines #TL1A #BloodTest #Capsule #BrainGut #Microbiome https://www.gastroendopod.com

🎧 Gastroenterology & Endoscopy Weekly Update | July 30, 2025 This week delivered game-changing developments across diagnostics, treatment, and clinical practice. From AI proving its effectiveness in real-world endoscopy to breakthrough therapies for previously "undruggable" cancers, here's what you need to know for your practice. 🔬 RESEARCH HIGHLIGHTS AI Endoscopy Meta-Analysis: Comprehensive review of 569 studies shows AI significantly outperforms conventional endoscopy for GI tumor detectionMATTERHORN Trial Results: Imfinzi + chemotherapy reduces disease progression risk by 30% in early gastric/GEJ cancersThailand AI Approval: First country approves AI diagnostic system with 81% accuracy for gastric adenocarcinoma detection💊 FDA & REGULATORY NEWS Geneoscopy ColoSense: Simplified stool collection approved - eliminates scraping requirement, maintains 93% CRC sensitivityImfinzi Priority Review: Breakthrough Therapy designation for first potential perioperative immunotherapy in gastric cancerVS-7375 Fast Track: KRAS G12D inhibitor for pancreatic cancer shows 52% response rate, 100% disease control📋 PRACTICE UPDATES New ASGE GERD Guidelines: TIF procedures now recommended as PPI alternative for appropriate candidatesEndohepatology Advances: EUS-guided procedures expanding options for liver disease managementAGA Gender Equity Framework: Six-domain approach to addressing workforce diversity challenges⚡ CLINICAL TAKEAWAYS ✅ Prepare for AI-assisted endoscopy integration in your practice ✅ Consider simplified stool tests for screening-resistant patients ✅ Implement updated GERD procedural guidelines ✅ Explore endohepatology techniques for cirrhotic patients 🎯 KEY STATISTICS 44 million Americans aged 45-75 remain unscreened for colorectal cancerEarly gastric cancers missed in 4.5-25.8% of conventional endoscopies100% sensitivity achieved for CRC screening in 45-49 age group with new collection method📚 SOURCES All information compiled from peer-reviewed journals, FDA announcements, and major GI society publications from July 24-30, 2025. ⚠️ DISCLAIMER This content is for educational purposes only. Always consult primary sources and official guidelines for clinical decision-making. #Gastroenterology #Endoscopy #AIinMedicine #ColorectalCancer #PancreaticCancer #GERD #ClinicalUpdates https://www.gastroendopod.com

In this episode the hosts dive into the latest breakthroughs in gastroenterology and hepatology. From immunotherapy's shift to earlier cancer treatments and new discoveries in IBD, to AI-driven diagnostics and policy impacts on preventive care, the discussion highlights a move toward precise, less invasive, and collaborative patient care. Packed with insights on cancer, liver health, endoscopy, and more, this episode distills key developments without overwhelming the listener. 00:00 - Introduction and OverviewWelcome to the podcast and a high-level preview of breakthroughs in gastroenterology, hepatology, cancer treatments, IBD, liver health, and endoscopy techniques. The hosts emphasize pulling out key nuggets for listeners without overload, focusing on shifts toward precise and collaborative care.00:41 - Immunotherapy in Colorectal and Gastric CancerDiscussion on the transformative shift to using immune checkpoint inhibitors earlier in treatment, including perioperative and adjuvant settings for curative intent. Highlights the ATOMIC trial's 50% reduction in recurrence or death for Stage 3 colon cancer patients, challenges in implementation, and the need for multidisciplinary collaboration.01:54 - Early Cancer Detection: Sentinel Polyp and Risk AssessmentExploration of the "sentinel polyp" concept, where a single high-risk polyp (e.g., with high-grade dysplasia) may predict future cancer risk better than polyp count alone. This challenges current surveillance strategies, emphasizing quality over quantity in lesion assessment.02:37 - Germline Mutations in Esophageal AdenocarcinomaFindings that about 9% of esophageal adenocarcinoma patients have inherited mutations, paving the way for personalized genetic screening similar to BRCA testing for breast cancer.02:55 - Inflammatory Bowel Disease (IBD): ETS2 Pathway DiscoveryLandmark identification of the ETS2 pathway as a central driver of inflammation in IBD. Exciting potential for repurposing MEK inhibitors (from oncology) to "turn down" inflammation, ushering in a precision IBD era with tailored treatments based on molecular profiles.03:47 - Liver Health Advances: Aspirin, Cell Therapy, and AIPromising use of low-dose aspirin to reduce liver fat in metabolic dysfunction-associated steatotic liver disease (MASLD). Early results from macrophage cell therapy showing zero liver-related events in advanced cirrhosis patients. Plus, AI's role in hepatocellular carcinoma (HCC) detection, often outperforming human experts on ultrasounds.05:00 - Endoscopy Innovations: Balancing Complexity and Non-InvasivenessDuality in endoscopy: Advanced procedures like endoscopic submucosal tunneling resection for stomach tumors (less invasive than surgery), contrasted with non-invasive tools like the capsule sponge test for Barrett's esophagus to defer procedures in low-risk patients, optimizing resources.05:55 - Health Policy: Supreme Court on Preventive CareU.S. Supreme Court's upholding of the Affordable Care Act's preventive services, ensuring no-cost access to screenings like colorectal cancer tests. Connects policy to clinical innovations, stressing its role in delivering breakthroughs to patients.06:36 - Wrap-Up: Seismic Shifts and Future ImplicationsSummary of the episode's themes, highlighting rapid progress in GI care through science, AI, and collaboration. Poses questions on how data science, policy, and AI will redefine the gastroenterologist's role in a dynamic future. https://www.gastroendopod.com

This week's episode covers the first FDA-approved ingestible gas-sensing capsule, AI-powered endoscopy with spatial computing, promising Crohn's disease therapeutics, and important regulatory updates affecting clinical practice. Revolutionary Diagnostic Technology (00:00 - 01:20) Atmo Biosciences FDA Clearance: First ingestible gas-sensing capsule for gut motility disordersEliminates need for gastric scintigraphy and radio-opaque marker studiesValidated in 209-subject pivotal clinical study across 12 sitesAvailable July 2025AI and Spatial Computing in Endoscopy (01:20 - 02:33) Cosmo Pharmaceuticals + Apple Vision Pro: First clinical study combining AI endoscopy with spatial computingGI Genius AI system integration with Apple Vision Pro headset14.4% increase in adenoma detection ratesStudy begins July 2025 at Rush University Medical Center (Dr. Irving Waxman)Fujifilm EC-860P: New slim colonoscope with enhanced imaging capabilitiesClinical Trial Breakthroughs (02:33 - 03:59) Tulisokibart for Crohn's Disease: APOLLO-CD trial results50% clinical remission vs. 16% historical controlsTL1A protein targeting with precision medicine approachGeneoscopy ColoSense: Real-world screening performance data14% reduction in CRC deaths vs. FIT testing86% reduction vs. blood-based testsRegulatory Updates and Quality Concerns (03:59 - 05:38) FDA Import Alert - Olympus: Restrictions on Aizu facility devicesAffects bronchoscopes, laparoscopes, ureterorenoscopesQuality system violations and compliance issuesNitinotes EndoZip: FDA IDE approval for automated ESG platform184-patient pivotal trial across 10 US sitesProfessional Guidelines and Market Consolidation (05:38 - 06:58) ACG/WGO H. pylori Guidelines: Updated treatment recommendationsEmphasis on clarithromycin resistance testingAGA Crohn's Disease Guidelines: Public comment period through July 20, 2025Torrent-JB Pharmaceuticals: $3.01 billion acquisitionClinical Implications and Future Outlook (06:58 - 08:22) Integration recommendations for clinical practiceConvergence of AI, spatial computing, and precision medicineFuture of gastroenterology practice Published Research "Tulisokibart for Crohn's Disease: APOLLO-CD Trial Results"The Lancet Gastroenterology & Hepatology50% clinical remission rate in moderate-to-severe Crohn's diseaseCedars-Sinai study led by Dr. Dermot McGovern"ColoSense Real-World Screening Impact Study"Clinical Gastroenterology and Hepatology10-year Markov modeling studySuperior performance vs. FIT and blood-based tests"Atmo Biosciences Gas-Sensing Capsule Validation Study"Pivotal clinical study: 209 subjects across 12 sites (11 US, 1 Australia)FDA 510(k) clearance for gut motility disordersClinical Trials in Progress Cosmo Pharmaceuticals AI + Apple Vision Pro StudyRush University Medical CenterPrincipal Investigator: Dr. Irving WaxmanStudy initiation: July 2025Nitinotes EndoZip Pivotal Trial184 patients across 10 US sitesRandomized controlled trial vs. FDA-approved devicePatient enrollment: Q3 2025 https://www.gastroendopod.com

In This Episode, We Cover: Statins as Liver Protectors: A landmark study from Harvard and Mass General reveals that statins can significantly reduce the risk of liver cancer and other complications. The longer you take them, the better the protective benefits.A Palatable New Diet for GI Distress: Researchers at Cedars-Sinai have developed a new elemental diet that patients can actually stick to. This could be a game-changer for individuals with conditions like IBS, SIBO, and Crohn's disease.A Silver Lining for Pancreatitis Patients: A major study shows that GLP-1 receptor agonists, often used for weight loss and diabetes, can dramatically lower the risk of acute pancreatitis in those with chronic pancreatitis.Smarter Crohn's Disease Management: The CURE-CD trial highlights the success of using video capsule endoscopy to guide treatment, leading to fewer flare-ups for high-risk patients.The "Why" Behind the Earlier Colonoscopy Age: Recent data from Kaiser Permanente validates the recommendation to begin colorectal cancer screening at age 45, showing similar rates of concerning polyps and cancer in the 45-49 age group as in the 50-54 group.Journal Watch: A quick look at other important research from early 2025, including advances in esophageal motility disorders, gastroparesis, and celiac disease.Disclaimer: The information in this podcast is for educational purposes only and should not be taken as medical advice. Please consult with your healthcare provider for any personal health concerns. https://www.gastroendopod.com

This episode analyzes pivotal developments in gastroenterology and endoscopy for June 10-16, 2025. The host examines breakthrough IBD therapeutics, revolutionary endoscopic technologies, and updated clinical guidelines that are reshaping practice standards (00:05). Then, we explore cutting-edge AI integration in diagnostic procedures and the clinical implications of new capsule endoscopy advances (02:33). Finally, we discuss the European approval of TREMPFIA as a dual IL-23 inhibitor and evaluate how emerging biosimilars are transforming patient access to specialty care (05:57). Clinical Practice Integration Points: Advanced Endoscopic Technologies - Olympus EZ1500 approval represents significant imaging enhancement with improved depth of field and ergonomic design, while Medtronic's PillCam Genius SB introduces real-time patient alert capabilities that fundamentally change small bowel surveillance protocols. Evidence-Based Guideline Updates - ACG's refined ulcerative colitis management emphasizes personalized diagnostics with prioritized stool testing and systematic disease activity monitoring, while new gastric cancer screening protocols target high-risk populations using the Sydney Protocol framework. Therapeutic Advancement Pipeline - TREMPFIA's dual IL-23 inhibition mechanism for both UC and Crohn's disease, coupled with expanding biosimilar access, represents a paradigm shift in IBD treatment accessibility and clinical outcomes optimization. Key Technical Insights: NaviCam ProScan AI demonstrates measurable efficiency gains in small bowel bleeding detection90%+ bowel preparation adequacy standards now mandatory across all provider networks3-year surveillance intervals established for high-risk gastric conditions requiring systematic biopsy protocolsA big thank you to this week's sponsor: DigestiveJobs.com - Find gastroenterology, hepatology and endoscopy careers worldwide. Post your GI job FREE this month! Visit DigestiveJobs.com https://www.gastroendopod.com

Major breakthroughs reshape GI practice this week: AI-assisted colonoscopy proves it can boost adenoma detection rates by 20 percentage points while saving time, the first nutrition diagnostic meets FDA endpoints for IBS management, and new Kaiser data reinforces screening at age 45. Plus, updates on neonatal malabsorption therapy, GI practice consolidation, and the booming OR integration market. 🤖 AI Colonoscopy Reaches New Milestone World Journal of Gastroenterology publishes 47-page state-of-the-art reviewCADe platforms increase ADR by average of 20 percentage pointsShortens withdrawal time by 45 secondsAuthors call for cost-effectiveness studies and standardized trainingRead the full review🍽️ Breakthrough IBS Food Test Meets FDA Endpoints Biomerica's inFoods® IBS test achieves primary endpoint in RCT238 patients across 8 U.S. academic centersFDA pain-responder rate: 59.6% vs 42.2% (placebo diet)Strongest efficacy in IBS-M: 66% respondersFirst nutrition diagnostic to meet prespecified IBS endpointsPublished in Gastroenterology    🏥 Practice Consolidation Update Dignity Health acquires Sierra Nevada GastroenterologyGrass Valley, CA clinic closes June 9, reopens June 16Includes endoscopy suite upgrades and EPIC integrationReflects ongoing health system consolidation trend👶 First Neonatal Malabsorption Drug Trial Begins Elgan Pharma & Chiesi launch Phase 3 NEOMAL studyELGN-2112 for very-low-birth-weight neonates (n≈240)Primary endpoint: weight-for-age z-score at 6 weeksCould become first pharmacologic therapy for condition📊 CRC Screening at 45 Validated Kaiser Northern California cohort study in JAMA25,000 patients comparing ages 45-49 vs 50-54Similar rates of advanced adenoma, serrated lesions, CRCOnly difference: adenoma prevalence (35.4% vs 40.8%)Reinforces USPSTF/ACS guidelines💻 OR Integration Market Forecast Market projected to reach $6.9 billion by 20315% CAGR driven by 4K imaging, cloud routing, hybrid suitesHospitals bundling AI-ready colonoscopy platformsCapital planning implications for 2026Key Takeaways AI in colonoscopy is ready for prime time - but needs proper implementationPersonalized nutrition arrives for IBS - test-guided diets outperform placeboAge 45 screening is evidence-based - update your protocols nowConsolidation continues - independent groups need strategic planningTech investment is mandatory - 4K and AI capabilities becoming standardResources & References AI Colonoscopy Review (World J Gastroenterol 2025)inFoods® IBS RCT (Gastroenterology June 2025)Kaiser CRC Screening Study (JAMA June 2025)iData OR Integration Market Report (June 2025)NEOMAL Trial Registration (ClinicalTrials.gov) Episode Sponsor DigestiveJobs.com - Find gastroenterology, hepatology and endoscopy careers worldwide. Post your GI job FREE this month! Visit DigestiveJobs.com Disclaimer This podcast provides educational content for healthcare professionals. Information should not replace clinical judgment. Consult primary sources and guidelines for patient care decisions. https://www.gastroendopod.com

This episode is brought to you by DigestiveJobs.com Find gastroenterology, hepatology and endoscopy careers worldwide. Post your GI job free this month and reach top specialists fast on DigestiveJobs.com. This week's update covers the alarming global spread of IBD into developing nations, promising new therapies for eosinophilic GI diseases from DDW 2025, innovative endoscopic solutions for post-GLP-1 weight maintenance, and the integration of extended reality in endoscopic training. Plus, updates on pancreatic cancer trials, new endoscope reprocessing technology, and the latest in microbiome research. 🌍 IBD Global Expansion (2:15) New research shows IBD spreading to Africa, Asia, and Latin AmericaImplications for global healthcare strategiesGut microbiome as biomarker for GI disease detection🔬 Eosinophilic GI Disease Breakthroughs (4:30) Barzolvolimab: Novel mast cell depletion therapy for EoEDupilumab: Expanding benefits from EoE to eosinophilic gastritisEREFS validation: Predicting disease outcomes in EoESocial vulnerability impact on EoE presentation💊 Therapeutic Pipeline Updates (7:45) OSE Immunotherapeutics: Lusvertikimab targeting >50% remission in UC subpopulationPredictive biomarker integration for enhanced treatment selection🏋️ Post-GLP-1 Weight Management (9:30) Fractyl Health & Bariendo partnership: Revita® procedureEndoscopic duodenal lining treatment for weight maintenanceData readouts expected June 2025🔧 Technology & Innovation (11:15) Olympus ScopeLocker Air: New endoscope drying cabinet meeting society guidelinesExtended Reality in Training: AR/VR for colorectal surgery and endoscopyAI-assisted polyp detection integration🎗️ Oncology Updates (13:00) EBC-129: FDA fast track designation for advanced pancreatic cancerPhase 1 trial showing encouraging activity in PDACASCO 2025 GI cancer updates forthcoming🦠 Infectious Disease Relevance (14:30) Fidaxomicin updates for C. difficile managementMicrobiome therapy safety profiles (Vowst)Key Takeaways IBD is no longer a "Western disease" - global strategies neededEosinophilic GI diseases seeing multiple therapeutic advancesEndoscopic solutions emerging for GLP-1 discontinuation challengesVirtual reality transforming endoscopic trainingBiomarker-driven approaches improving IBD treatment selectionResources & References DDW 2025 Eosinophilic Disease Highlights (Apfed)Olympus ScopeLocker Air Launch (BioSpace)OSE Immunotherapeutics Pipeline Update (BioSpace)Fractyl Health Revita® Procedure Development (Stock Titan)Extended Reality in Colorectal Training (BMJ Frontline Gastroenterology)EBC-129 Pancreatic Cancer Trial (Targeted Oncology)Timestamps 0:00 - Introduction & Week Overview2:15 - Global IBD Expansion4:30 - DDW 2025 EoE/EoG Updates7:45 - UC Therapeutic Advances9:30 - Post-GLP-1 Weight Solutions11:15 - Endoscopy Technology Updates12:00 - XR/VR in Medical Training13:00 - Pancreatic Cancer Trial News14:30 - C. diff Management Updates15:45 - Closing & Next Week Preview This podcast provides educational content for healthcare professionals. Information presented should not replace clinical judgment or patient-specific treatment decisions. Always verify updates and consult primary sources for clinical application. https://www.gastroendopod.com

Join us as we delve into the revolutionary world of medical imaging, specifically focusing on two advanced endoscopy techniques: Narrow Band Imaging (NBI) and Blue Light Imaging (BLI). Discover how these image-enhanced technologies utilize specific light wavelengths to dramatically improve the visualization and diagnosis of various medical conditions. We'll explore the science behind each technique, their diverse applications across different medical fields, and how they are changing the landscape of patient care. Key Topics Discussed: Introduction to Image-Enhanced Endoscopy: Understanding how NBI and BLI enhance visualization of mucosal surfaces and blood vessels.Narrow Band Imaging (NBI):How NBI uses specific blue and green light wavelengths.The science behind hemoglobin absorption and the resulting contrast in images (brown capillaries, cyan veins).Blue Light Imaging (BLI):The blue light spectrum used in BLI.How BLI interacts with tissue to reveal hidden structures.Blue Light Cystoscopy (BLC) and Hexaminolevulinate (HAL): Explanation of this specialized application for bladder cancer detection, where HAL causes cancerous cells to glow.Applications Across Medical Fields:Gastroenterology: Detection and characterization of colorectal polyps, early gastric cancer detection (BLI-bright), diagnosis of Barrett's esophagus and inflammatory bowel disease (NBI).Urology: Highly effective bladder cancer detection with BLI and HAL, NBI's role in non-muscle invasive bladder cancer and upper urinary tract examination.Pulmonology: Visualization of the bronchial mucosa for lung cancer detection and staging using NBI.Head and Neck Surgery: NBI for assessing surgical margins after procedures like Transoral Laser Microsurgery.Advantages and Considerations of NBI and BLI:NBI's excellent contrast for mucosal surfaces and blood vessels.BLI's potential for high-resolution images (especially BLI-bright).Cost considerations: NBI often being less expensive, BLI systems potentially more costly.Variability in availability of different systems.Linked Color Imaging (LCI): A brief overview of LCI and its benefits, including brighter views and enhanced polyp visibility.Choosing Between NBI and BLI: Highlighting that the best choice depends on the specific situation and the potential benefits of combining techniques.Key Terms: Narrow Band Imaging (NBI)Blue Light Imaging (BLI)Image-Enhanced EndoscopyMucosal SurfacesHemoglobinCapillariesVeinsHexaminolevulinate (HAL)Blue Light Cystoscopy (BLC)Colorectal PolypsProximal AdenomasGastric CancerBarrett's EsophagusInflammatory Bowel DiseaseNon-Muscle Invasive Bladder CancerBronchial MucosaTransoral Laser MicrosurgeryLinked Color Imaging (LCI)Neoplastic LesionsTakeaways: NBI and BLI are powerful tools that significantly improve the visualization of tissue during endoscopic procedures.These techniques aid in the early detection and diagnosis of various conditions, including cancers.The choice between NBI and BLI often depends on the specific clinical need, and sometimes a combination of both is ideal.Ongoing advancements in imaging technology promise even better diagnostic capabilities in the futurehttps://www.gastroendopod.com

H. pylori Antibiotic Resistance: A Growing Medical Crisis In this comprehensive episode, we dive deep into the growing challenge of H. pylori antibiotic resistance and its impact on global healthcare. Learn about the latest treatment approaches, resistance patterns, and future therapeutic solutions. Key Topics Covered: • Understanding H. pylori and its survival mechanisms • Global prevalence and infection rates • Antibiotic resistance patterns across regions • Treatment protocols and their effectiveness • Emerging therapeutic approaches 📊 Important Statistics: - Global infection rate: 4.4 billion people affected - Clarithromycin resistance: 15.2% (North America) vs 32.5% (Asia) - Metronidazole resistance: 26.7% (North America) vs 47.6% (Asia) - Treatment success rates: 60-90% depending on resistance patterns 💡 Key Insights: 1. Traditional triple therapy becoming less effective 2. Quadruple therapy showing promise (85-95% success rate) 3. Probiotics improving eradication rates by up to 13% 4. Molecular diagnostics revolutionizing treatment approaches 🔬 Treatment Protocols Discussed: - Triple Therapy - Quadruple Therapy - Sequential Therapy - Bismuth-based regimens 🔮 Future Developments: • Antimicrobial peptides • Nanotechnology-based delivery systems • Vaccine development • Personalized medicine approaches 📚 Additional Resources: https://gastroscholar.com/h-pylori-antibiotic-resistance-treatment-challenges/ 🎯 Target Audience: Medical professionals, healthcare practitioners, and specialists interested in gastroenterology and infectious diseases. https://www.gastroendopod.com

The Gastroenterology & Endoscopy Podcast Episode 147: Endoscopic Management of Premalignant Lesions Quick Summary: An evidence-based overview of EMR vs ESD for premalignant lesions, including technique selection, outcomes, and complication rates. Key Points: • EMR: Preferred for lesions 20mm, 83-98% en bloc resection rate • Technique selection based on lesion size, location, and suspected invasion • Watch for delayed bleeding and stricture formation Essential Reading: 1. ASGE Guidelines on ESD    https://www.asge.org/docs/default-source/guidelines/asge-guideline-on-endoscopic-submucosal-dissection 2. Cleveland Clinic EMR Protocol    https://my.clevelandclinic.org/health/treatments/21148-endoscopic-mucosal-resection 3. Mayo Clinic ESD Guide    https://www.mayoclinic.org/medical-professionals/digestive-diseases/news/esophageal-endoscopic-submucosal-dissection/mac-20552628 Additional Resources: • Clinical Outcomes Study - https://www.sciencedirect.com/science/article/abs/pii/S0016510712023760 • ESD Technical Analysis - https://pmc.ncbi.nlm.nih.gov/articles/PMC3072634/ • Comparative Review - https://pmc.ncbi.nlm.nih.gov/articles/PMC5824597/ • Technical Developments - https://www.sciencedirect.com/science/article/abs/pii/S0960740422000354 https://www.gastroendopod.com

In this episode of the GI Endoscopy Update Podcast, Dr. Sarah Thompson explores the latest advancements in artificial intelligence (AI) for gastrointestinal endoscopy. Key topics include: Recent breakthroughs in video capsule endoscopyAI applications in colonoscopy and lesion characterizationAdvancements in esophageal neoplasia detectionBenefits of AI integration in endoscopic practiceChallenges and limitations of AI implementationFuture prospects for AI in GI endoscopyKey takeaways: AI significantly improves diagnosis accuracy and efficiencyChallenges include over-reliance risks and technical limitationsFuture developments may include integration with EHRs and personalized medicineSources and Resources: Ding et al. (Study on AI software for small-bowel abnormalities diagnosis)Zhang et al. (Research on magnetically guided capsule for gastric diagnosis)Mori et al. (Algorithms for colonoscopy image analysis)Hossain et al. (Study on AI in lesion characterization)Everson et al. (Research on AI for esophageal neoplasia detection)Medtronic and Modernizing Medicine collaboration (Integration of AI with EHR systems)https://www.gastroendopod.com